| Literature DB >> 28811074 |
J M Aguado1, J T Silva2, M Fernández-Ruiz3, E Cordero4, J Fortún5, C Gudiol6, L Martínez-Martínez7, E Vidal8, L Almenar9, B Almirante10, R Cantón11, J Carratalá6, J J Caston8, E Cercenado12, C Cervera13, J M Cisneros4, M G Crespo-Leiro14, V Cuervas-Mons15, J Elizalde-Fernández16, M C Fariñas17, J Gavaldà10, M J Goyanes12, B Gutiérrez-Gutiérrez18, D Hernández19, O Len10, R López-Andujar20, F López-Medrano3, P Martín-Dávila5, M Montejo21, A Moreno22, A Oliver23, A Pascual18, E Pérez-Nadales8, A Román-Broto24, R San-Juan3, D Serón25, A Solé-Jover26, M Valerio12, P Muñoz12, J Torre-Cisneros27.
Abstract
Solid organ transplant (SOT) recipients are especially at risk of developing infections by multidrug resistant (MDR) Gram-negative bacilli (GNB), as they are frequently exposed to antibiotics and the healthcare setting, and are regulary subject to invasive procedures. Nevertheless, no recommendations concerning prevention and treatment are available. A panel of experts revised the available evidence; this document summarizes their recommendations: (1) it is important to characterize the isolate's phenotypic and genotypic resistance profile; (2) overall, donor colonization should not constitute a contraindication to transplantation, although active infected kidney and lung grafts should be avoided; (3) recipient colonization is associated with an increased risk of infection, but is not a contraindication to transplantation; (4) different surgical prophylaxis regimens are not recommended for patients colonized with carbapenem-resistant GNB; (5) timely detection of carriers, contact isolation precautions, hand hygiene compliance and antibiotic control policies are important preventive measures; (6) there is not sufficient data to recommend intestinal decolonization; (7) colonized lung transplant recipients could benefit from prophylactic inhaled antibiotics, specially for Pseudomonas aeruginosa; (8) colonized SOT recipients should receive an empirical treatment which includes active antibiotics, and directed therapy should be adjusted according to susceptibility study results and the severity of the infection.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28811074 DOI: 10.1016/j.trre.2017.07.001
Source DB: PubMed Journal: Transplant Rev (Orlando) ISSN: 0955-470X Impact factor: 3.943